Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase activation in subjects with non ‐alcoholic fatty liver disease

ConclusionsEmricasan decreased ALT and biomarkers in subjects with NAFLD and raised aminotransferases after 28 days. These results support the further development of emricasan in patients with NAFLD. Trial registration: ClinicalTrials.gov, Identifier: NCT02077374.

https://onlinelibrary.wiley.com/doi/abs/10.1111/apt.15030?af=R

Source: Alimentary Pharmacology and Therapeutics - November 14, 2018 Category: Drugs & Pharmacology Authors: Mitchell Shiffman, Bradley Freilich, Raj Vuppalanchi, Kymberly Watt, Jean L. Chan, Al Spada, David T. Hagerty, Eugene Schiff Tags: RANDOMISED CLINICAL TRIAL Source Type: research